ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Salivary OMICS factors associated with atopic dermatitis in early infancy.
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salivary OMICS factors associated with atopic dermatitis in early infancy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) often develops in early childhood and may persist into adulthood. Noninvasive measures to identify infants at risk for AD are limited. We investigated whether oral biomarkers and oral microbiota are associated with AD onset within the first 2 years of life.
methodsIn this prospective cohort study, we followed 119 infants residing in Upstate New York from birth to 24 months (2018-2023). AD diagnoses were obtained from electronic health records. Saliva samples were collected at seven time points (1, 2, 4, 6, 12, 18, and 24 months) and analyzed for 5 hormones and 23 cytokines using multiplex immunoassays. Salivary microbiome profiles were characterized via metagenomic sequencing.
resultsNearly half (48%) of infants developed AD by age 2, with most cases manifesting by 12 months (42%) and peak incidence occurring between months 2-4. Infants who developed AD by 1 year demonstrated significantly elevated estradiol (p = .007) and progesterone (p = .046) at 1 month, and a significantly lower salivary cortisol level (p = .019) at 6 months. Additionally, these infants exhibited higher sIL-1ra (p = .024) and IL-9 (p = .034) in saliva at 4 months and lower IL-1α (p = .038) at 6 months. Salivary microbiome beta diversity differed significantly at 2 months between infants with and without AD by 1 year (p = .038), with lower differential abundances of Bifidobacterium breve and Veillonella atypica in early infancy prior to AD onset.
conclusionEarly-life salivary biomarkers, including hormonal, cytokine, and microbiome signatures, may serve as noninvasive indicators of infants at risk for early AD onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.